Expert insights. Personalized for you.
29 percent of Americans said they were unlikely to get vaccinated — up from 24 percent three months earlier. Most workers do not want their own employer to require vaccination, including the vast majority of unvaccinated workers (92%). The post Is it time for vaccination mandates? MORE
The government has the latitude to protect citizens from deadly conditions, especially when the science supporting vaccination is so clear” We, as a nation, can not allow ignorance and stupidity to endanger us all. were for people who skipped out on getting vaccinated. MORE
Positive results from Clover's Phase 3 study could mean another coronavirus vaccine option for the many countries still grappling with short supplies MORE
While health officials have documented more cases of a rare blood clotting syndrome associated with J&J's vaccine, a CDC committee supported use of the shot with an added warning MORE
Scientists at Stanford University and the University of North Carolina at Chapel Hill have created a 3D-printed vaccine patch that provides greater protection than a typical vaccine shot. Social & Behavioral Science offers patch printed shot vaccination vaccine MORE
SUMMARY : Vaccine mandates are only going to get us so far when it comes to COVID immunity. The reasons for people refusing vaccines are both safety and side effect concerns, although politics plays a big part as well. As I See It COVID Vaccine MORE
So far, both Pfizer's and Moderna's vaccines appear to work against more transmissible variants, but preparation is underway for the day they don't MORE
The government-funded trial will evaluate the effects of mixing vaccines and varying timing between shots MORE
Drones have emerged as a speedy logistics option for time- and temperature-sensitive vaccine doses, potentially helping boost the availability of shots in rural areas MORE
Moderna is facing criticism for refusing to share its COVID-19 vaccine formula amid global vaccine shortages and continuing COVID-19 vaccine inequities. However, on Tuesday, Moderna told The Associated Press that it has “no plans to share the recipe for its COVID-19 vaccine.” MORE
The first public vaccinations with AstraZeneca and Oxford’s shot will begin early in the New Year. But it’s still unclear how effective the vaccine is, or the best way to use it MORE
A CDC advisory panel is expected to vote on Friday to recommend the additional dose, after which certain people with weakened immune systems can receive a third shot of Pfizer's or Moderna's vaccine MORE
The company has previously said it could make up to three billion vaccine doses in 2022, depending on how booster shots are authorized MORE
SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others. MORE
SUMMARY: Johnson & Johnson and AstraZeneca publicly committed to not profiting off their products during the pandemic; Pfizer and Moderna made no such pledge and are already planning ways to make more money from their Covid vaccines. The post Profiteering off a Covid vaccine. MORE
QUICK READ : Pharma had a chance to earn some goodwill with a very skeptical public but it’s become obvious that the rush to develop a vaccine is about profit, executive stock, and Wall Street despite potential huge investments from the government. in the news COVID Vaccine MORE
SUMMARY: Even though the Delta variant of COVID is highly contagious, people are still choosing not to get vaccinated. Concerns about safety, fear of unknown side effects, and misinformation about COVID-19 are some reasons why people may not accept the vaccine. MORE
QUICK READ : The government is agreeing to pay billions of dollars to the first company that developed a COVID-19 vaccine. billion for 100 million doses of a vaccine made by Pfizer Inc. The question that the media is asking is “will consumers trust a COVID-19 vaccine?” MORE
While Canada has already secured more COVID-19 vaccine doses than it needs, the factory to be built is geared toward combating future pandemics MORE
You need to ask yourself why in the hell Pfizer’s CEO would say that their vaccine is 90% effective when there is a lot more testing and review of data needed. However, there’s still a long way to go before researchers can be certain that this vaccine is indeed as effective as promised. MORE
Highly anticipated results from a Phase 3 study testing the biotech company's shot showed it to be strongly protective and safe, a potential boon for the world's vaccination efforts MORE
The study found that the shots’ effectiveness in preventing hospitalization fell to 77 percent from 91 percent four months after full vaccination. Vaccination and Immunization Drugs (Pharmaceuticals) Research BioNTech SE Centers for Disease Control and Prevention Pfizer Inc MORE
A panel of vaccine and infectious disease experts will publicly vet the drugmakers' study results on Thursday. Follow the discussion along with BioPharma Dive reporters here MORE
These differences also explain why vaccines are necessary for both the flu and COVID-19. Read more Flu Vaccine vs. COVID-19 Vaccine. The post Flu Vaccine vs. COVID-19 Vaccine appeared first on MyLocalStudy.com. MORE
The drugmaker will use production lines at its plant in McPherson, Kansas to help fill vaccine vials, company CEO Albert Bourla said Friday MORE
SUMMARY: The numbers game for COVOD-19 vaccine makers has started but what most of the public, and the media, don’t understand is that the preliminary numbers don’t mean a damn thing until they are peer-reviewed. As I See It COVID Vaccine MORE
A deal to fill vials of Pfizer and BioNTech's vaccine could be the first of several Novartis signs to help others make COVID-19 treatments MORE
The sum is $11 billion higher than Pfizer had estimated in February and, if realized, would make the vaccine the highest grossing pharmaceutical product by revenue in a single year MORE
Yearly vaccinations could be required after the pandemic ebbs. Will drugmakers change how they approach pricing their shots MORE
The agency's emergency clearance makes J&J's vaccine the third available in the U.S., adding much-needed reinforcements at a critical time MORE
The emergency clearance greatly expands the pool of people who can be vaccinated in the U.S. just as some states are beginning to report waning demand MORE
The move was expected to kick off a round of new vaccination mandates from hospitals, schools and private companies. MORE
A vaccine co-developed by the U.K. academic center and the Maryland biotech could be the first to meet the WHO's efficacy target for a malaria vaccine MORE
Agency advisers unanimously supported offering a second dose of J&J's coronavirus vaccine to adults who previously received it, though guidance could change as regulators evaluate mixing boosters MORE
An interim analysis conducted after 94 cases of COVID-19 in Pfizer and BioNTech's large study found their vaccine to be more than 90% effective MORE
The long-awaited decision could strengthen the case for vaccine mandates as public health officials seek to boost rates of immunization amid a wave of COVID-19 cases MORE
Marion Gruber and Phil Krause, two veteran vaccine reviewers, are unexpectedly leaving the agency at a critical time. The search for their replacements will begin "imminently," division head Peter Marks said in a letter MORE
The biotech company expects to make its coronavirus vaccine and mRNA shots for other diseases at the planned plant, into which it will invest $500 million MORE
One vaccine batch being manufactured for J&J by Emergent Biosolutions failed quality checks, reportedly ruining material sufficient for up to 15 million doses MORE
The drugmaker, one of the largest vaccine developers globally, won't move forward with either of two candidates it's been testing after disappointing data in early trials MORE
(Mckinsey) Much of the prevailing market research on COVID-19 vaccination frames sentiment as “likely,” “unlikely,” or “neutral.” Their research has found that consumers’ attitudes towards receiving a COVID-19 vaccine fall into three primary segments. in the news COVID Vaccine MORE
Having proved mRNA's might in COVID-19, the biotech company aims to develop similar vaccines for other respiratory illnesses caused by influenza, RSV and metapneumovirus MORE
Agency scientists noted the shot's strong protection against severe COVID-19, even for the virus variant first detected in South Africa and known to weaken vaccine potency MORE
The government has latitude to protect citizens from deadly conditions, especially when the science supporting vaccination is so clear” With respect to children, parents do not have carte blanche. The post The Constitution and vaccinations. in the news Vaccinations & the law MORE
Vaccination Related Topics World of DTC Marketing
AUGUST 26, 2021
The government has latitude to protect citizens from deadly conditions, especially when the science supporting vaccination is so clear” With respect to children, parents do not have carte blanche. The post The Constitution and vaccinations. in the news Vaccinations & the law
World of DTC Marketing
JULY 20, 2021
29 percent of Americans said they were unlikely to get vaccinated — up from 24 percent three months earlier. Most workers do not want their own employer to require vaccination, including the vast majority of unvaccinated workers (92%). The post Is it time for vaccination mandates?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
SEPTEMBER 10, 2021
The government has the latitude to protect citizens from deadly conditions, especially when the science supporting vaccination is so clear” We, as a nation, can not allow ignorance and stupidity to endanger us all. were for people who skipped out on getting vaccinated.
World of DTC Marketing
NOVEMBER 10, 2020
You need to ask yourself why in the hell Pfizer’s CEO would say that their vaccine is 90% effective when there is a lot more testing and review of data needed. However, there’s still a long way to go before researchers can be certain that this vaccine is indeed as effective as promised.
World of DTC Marketing
MARCH 25, 2021
SUMMARY: Johnson & Johnson and AstraZeneca publicly committed to not profiting off their products during the pandemic; Pfizer and Moderna made no such pledge and are already planning ways to make more money from their Covid vaccines. The post Profiteering off a Covid vaccine.
Scienmag
SEPTEMBER 24, 2021
Scientists at Stanford University and the University of North Carolina at Chapel Hill have created a 3D-printed vaccine patch that provides greater protection than a typical vaccine shot. Social & Behavioral Science offers patch printed shot vaccination vaccine
World of DTC Marketing
SEPTEMBER 27, 2021
SUMMARY : Vaccine mandates are only going to get us so far when it comes to COVID immunity. The reasons for people refusing vaccines are both safety and side effect concerns, although politics plays a big part as well. As I See It COVID Vaccine
World of DTC Marketing
JULY 19, 2021
SUMMARY: Even though the Delta variant of COVID is highly contagious, people are still choosing not to get vaccinated. Concerns about safety, fear of unknown side effects, and misinformation about COVID-19 are some reasons why people may not accept the vaccine.
World of DTC Marketing
JANUARY 8, 2021
SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others.
World of DTC Marketing
NOVEMBER 16, 2020
SUMMARY: The numbers game for COVOD-19 vaccine makers has started but what most of the public, and the media, don’t understand is that the preliminary numbers don’t mean a damn thing until they are peer-reviewed. As I See It COVID Vaccine
World of DTC Marketing
DECEMBER 11, 2020
(Mckinsey) Much of the prevailing market research on COVID-19 vaccination frames sentiment as “likely,” “unlikely,” or “neutral.” Their research has found that consumers’ attitudes towards receiving a COVID-19 vaccine fall into three primary segments. in the news COVID Vaccine
Bio Pharma Dive
AUGUST 23, 2021
The long-awaited decision could strengthen the case for vaccine mandates as public health officials seek to boost rates of immunization amid a wave of COVID-19 cases
Bio Pharma Dive
AUGUST 25, 2021
Drones have emerged as a speedy logistics option for time- and temperature-sensitive vaccine doses, potentially helping boost the availability of shots in rural areas
XTalks
OCTOBER 15, 2021
Moderna is facing criticism for refusing to share its COVID-19 vaccine formula amid global vaccine shortages and continuing COVID-19 vaccine inequities. However, on Tuesday, Moderna told The Associated Press that it has “no plans to share the recipe for its COVID-19 vaccine.”
Bio Pharma Dive
SEPTEMBER 8, 2021
The company has previously said it could make up to three billion vaccine doses in 2022, depending on how booster shots are authorized
Bio Pharma Dive
MAY 10, 2021
The emergency clearance greatly expands the pool of people who can be vaccinated in the U.S. just as some states are beginning to report waning demand
Bio Pharma Dive
AUGUST 31, 2021
Marion Gruber and Phil Krause, two veteran vaccine reviewers, are unexpectedly leaving the agency at a critical time. The search for their replacements will begin "imminently," division head Peter Marks said in a letter
Bio Pharma Dive
FEBRUARY 19, 2021
The drugmaker will use production lines at its plant in McPherson, Kansas to help fill vaccine vials, company CEO Albert Bourla said Friday
Bio Pharma Dive
FEBRUARY 27, 2021
The agency's emergency clearance makes J&J's vaccine the third available in the U.S., adding much-needed reinforcements at a critical time
Bio Pharma Dive
JULY 7, 2021
Having proved mRNA's might in COVID-19, the biotech company aims to develop similar vaccines for other respiratory illnesses caused by influenza, RSV and metapneumovirus
Bio Pharma Dive
JUNE 14, 2021
Highly anticipated results from a Phase 3 study testing the biotech company's shot showed it to be strongly protective and safe, a potential boon for the world's vaccination efforts
Bio Pharma Dive
DECEMBER 30, 2020
The first public vaccinations with AstraZeneca and Oxford’s shot will begin early in the New Year. But it’s still unclear how effective the vaccine is, or the best way to use it
Bio Pharma Dive
OCTOBER 7, 2021
The biotech company expects to make its coronavirus vaccine and mRNA shots for other diseases at the planned plant, into which it will invest $500 million
Bio Pharma Dive
AUGUST 13, 2021
A CDC advisory panel is expected to vote on Friday to recommend the additional dose, after which certain people with weakened immune systems can receive a third shot of Pfizer's or Moderna's vaccine
Bio Pharma Dive
OCTOBER 15, 2021
Agency advisers unanimously supported offering a second dose of J&J's coronavirus vaccine to adults who previously received it, though guidance could change as regulators evaluate mixing boosters
My Local Study
OCTOBER 1, 2020
These differences also explain why vaccines are necessary for both the flu and COVID-19. Read more Flu Vaccine vs. COVID-19 Vaccine. The post Flu Vaccine vs. COVID-19 Vaccine appeared first on MyLocalStudy.com.
Bio Pharma Dive
FEBRUARY 4, 2021
The government-funded trial will evaluate the effects of mixing vaccines and varying timing between shots
Bio Pharma Dive
FEBRUARY 24, 2021
Agency scientists noted the shot's strong protection against severe COVID-19, even for the virus variant first detected in South Africa and known to weaken vaccine potency
Bio Pharma Dive
MAY 4, 2021
The sum is $11 billion higher than Pfizer had estimated in February and, if realized, would make the vaccine the highest grossing pharmaceutical product by revenue in a single year
Bio Pharma Dive
JANUARY 28, 2021
So far, both Pfizer's and Moderna's vaccines appear to work against more transmissible variants, but preparation is underway for the day they don't
Bio Pharma Dive
JANUARY 29, 2021
A deal to fill vials of Pfizer and BioNTech's vaccine could be the first of several Novartis signs to help others make COVID-19 treatments
Bio Pharma Dive
FEBRUARY 9, 2021
Yearly vaccinations could be required after the pandemic ebbs. Will drugmakers change how they approach pricing their shots
Bio Pharma Dive
APRIL 1, 2021
One vaccine batch being manufactured for J&J by Emergent Biosolutions failed quality checks, reportedly ruining material sufficient for up to 15 million doses
Bio Pharma Dive
NOVEMBER 9, 2020
An interim analysis conducted after 94 cases of COVID-19 in Pfizer and BioNTech's large study found their vaccine to be more than 90% effective
Bio Pharma Dive
JANUARY 25, 2021
The drugmaker, one of the largest vaccine developers globally, won't move forward with either of two candidates it's been testing after disappointing data in early trials
World of DTC Marketing
JULY 22, 2020
QUICK READ : The government is agreeing to pay billions of dollars to the first company that developed a COVID-19 vaccine. billion for 100 million doses of a vaccine made by Pfizer Inc. The question that the media is asking is “will consumers trust a COVID-19 vaccine?”
Bio Pharma Dive
AUGUST 10, 2021
While Canada has already secured more COVID-19 vaccine doses than it needs, the factory to be built is geared toward combating future pandemics
Bio Pharma Dive
APRIL 23, 2021
A vaccine co-developed by the U.K. academic center and the Maryland biotech could be the first to meet the WHO's efficacy target for a malaria vaccine
Bio Pharma Dive
APRIL 23, 2021
While health officials have documented more cases of a rare blood clotting syndrome associated with J&J's vaccine, a CDC committee supported use of the shot with an added warning
NY Times
SEPTEMBER 17, 2021
The study found that the shots’ effectiveness in preventing hospitalization fell to 77 percent from 91 percent four months after full vaccination. Vaccination and Immunization Drugs (Pharmaceuticals) Research BioNTech SE Centers for Disease Control and Prevention Pfizer Inc
World of DTC Marketing
JULY 28, 2020
QUICK READ : Pharma had a chance to earn some goodwill with a very skeptical public but it’s become obvious that the rush to develop a vaccine is about profit, executive stock, and Wall Street despite potential huge investments from the government. in the news COVID Vaccine
Bio Pharma Dive
DECEMBER 9, 2020
A panel of vaccine and infectious disease experts will publicly vet the drugmakers' study results on Thursday. Follow the discussion along with BioPharma Dive reporters here
NY Times
AUGUST 23, 2021
The move was expected to kick off a round of new vaccination mandates from hospitals, schools and private companies.
243 
Let's personalize your content